The Davos Alzheimer’s Collaborative: Accelerating Transformative Innovation

The world urgently needs global collaboration to stop Alzheimer’s disease. The Davos Alzheimer’s Collaborative (DAC) is joining leading organizations in a bold cross-sector effort to meet this challenge – supporting coordination in the key areas needed to accelerate innovation.

Our Vision
DAC aims to create a global innovation ecosystem that changes the long-term trajectory of Alzheimer’s. By speeding the discovery, testing and delivery of precision interventions, DAC will enable a healthy, prosperous and productive future in an aging world.
To achieve that vision, we created DAC as a pre-competitive coalition focused on driving global, cross-sector scientific, business, policy and financial coordination in Alzheimer’s preparedness. DAC will focus global energy and investments on the areas most critical to developing and testing precision interventions – and then delivering them to the right patient at the right time.

Our Origin & Focus Areas
The idea for DAC began at the Lausanne Workshop – the world’s leading forum on Alzheimer’s innovation. Leaders and experts from across sectors posed a simple question: where can we significantly move the needle in the next five years?
The answer came a month later at the Davos World Economic Forum Meeting 2020, where DAC was conceived by private-sector executives, government leaders, NGOs and healthcare thought leaders. Since then, DAC has grown into a 6-year, ~$700 million plan to speed innovation in Alzheimer’s.
DAC stands apart because of the leadership, expertise and resources of our public- and private-sector members, our “link, scale, create” approach, and our focus on three essential areas:

• Global Cohort Development: DAC will work to increase targets for drug development and identify associated biomarkers to enable better understanding of the heterogeneity and the variability of Alzheimer’s etiology.

• Global Clinical Trials Support Platform: DAC will work to create a platform to support global clinical trials that reduce the cost and time to bring new treatments to market.

• Healthcare System Preparedness: DAC will work to ensure healthcare system readiness for broad access to new Alzheimer’s therapies.

Together, these elements will enable an innovation ecosystem that changes the trajectory of Alzheimer’s disease and addresses one of the great health and economic challenges of our time.

For more information about the Davos Alzheimer’s Collaborative, our seed funders and our expert advisors, please visit www.davosalzheimerscollaborative.org.